AmideBio LLC

AmideBio discovers and develops peptide therapeutics for metabolic diseases. The company uses advanced in-silico techniques to intelligently design novel peptides, its proprietary BioPure™ process to efficiently synthesize them and testing to assess their biological activity. We are currently developing drug candidates in congenital hyperinsulinism - an ultra orphan indication where there is no satisfactory therapy, and glucose responsive insulin - a safer insulin that avoids the risks of impaired awareness of hypoglycemia, a dangerous condition for patients with diabetes. AmideBio was founded in 2009 to commercialize BioPure platform technology to deliver difficult-to-manufacture, ultrapure peptides to the biopharmaceutical industry and research community. The company continues to sell these peptides to customers directly as well as offers a custom synthesis service. In 2016, the company began to leverage this capability to develop its own therapeutics targeting metabolic diseases.